Urology
Volume 73, Issue 5, Supplement , Pages S4-S10 , May 2009

Understanding the Epidemiology, Natural History, and Key Pathways Involved in Prostate Cancer

  • E. David Crawford

      Affiliations

    • Corresponding Author InformationReprint requests: E. David Crawford, M.D., Section of Urologic Oncology, University of Colorado Health Science Center, Mail Stop F710, P.O. Box 6510, Aurora, CO 80045

Received 2 February 2009 ,Accepted 2 March 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  2. Ries L, Melbert D, Drapcho M, et al. SEER cancer statistics review (based on November 2007 SEER data submission, posted to the SEER Web site, 2008). http://seer.cancer.gov/csr/1975_2005/Accessed May 30, 2008
  3. Garcia M, Jemal A, Ward E, et al. Global cancer facts and figures 2007. http://www.cancer.org/downloads/STT/Global_Cancer_Facts_and_Figures_2007_rev.pdfAccessed May 23, 2008
  4. Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control. 2004;15:237–241
  5. Boyle P, Severi G, Giles GG. The epidemiology of prostate cancer. Urol Clin North Am. 2003;30:209–217
  6. Yin M, Bastacky S, Chandran U, et al. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol. 2008;179:892–895
  7. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101(suppl):2371–2490
  8. Platz EA, Rimm EB, Willett WC, et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000;92:2009–2017
  9. Jones RA, Wenzel J. Prostate cancer among African-American males: understanding the current issues. J Natl Black Nurses Assoc. 2005;16:55–62
  10. Haqq C, Li R, Khodabakhsh D, et al. Ethnic and racial differences in prostate stromal estrogen receptor α. Prostate. 2005;65:101–109
  11. Platz EA, Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol. 2004;92:237–253
  12. Dunn JE. Cancer epidemiology in populations of the United States—with emphasis on Hawaii and California—and Japan. Cancer Res. 1975;35(11 Pt. 2):3240–3245
  13. Rodriguez C, McCullough ML, Mondul AM, et al. Meat consumption among black and white men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2006;15:211–216
  14. Park SY, Murphy SP, Wilkens LR, et al. Fat and meat intake and prostate cancer risk: the multiethnic cohort study. Int J Cancer. 2007;121:1339–1345
  15. Scardino PT. The Gordon Wilson lecture: natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc. 2000;111:201–241
  16. Greene DR, Shabsigh R, Scardino PT. Urologic Ultrasonography. In:  Walsh PC,  Retik AB,  Stamey TA, et al. editor. Campell's Urology. 6th ed.. Philadelphia, PA: W.B. Saunders; 1992;
  17. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990;143:742–746
  18. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242–248
  19. Johansson JE, Andrén O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713–2719
  20. Miller GJ, Torkko KC. Natural history of prostate cancer—epidemiologic considerations. Epidemiol Rev. 2001;23:14–18
  21. Theodorescu D. Prostate cancer, clinical oncology. In:  Schwab M editors. Encyclopedic Reference of Cancer. 1st ed.. New York: Springer Verlag; 2001;vol. 720
  22. McNeal JE. The zonal anatomy of the prostate. Prostate. 1981;2:35–49
  23. Byar DP, Mostofi FK. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies: examined by the step-section technique. Cancer. 1972;30:5–13
  24. Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 1994;152(5 Pt. 2):1709–1713
  25. Zhu YS, Sun GH. 5α-Reductase isozymes in the prostate. J Med Sci. 2005;25:1–12
  26. Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest. 1993;92:903–910
  27. Marks LS. 5α-Reductase: history and clinical importance. Rev Urol. 2004;6(suppl 9):S11–S21
  28. Wilbert DM, Griffin JE, Wilson JD. Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab. 1983;56:113–120
  29. Imperato-McGinley J, Guerrero L, Gautier T, et al. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974;186:1213–1215
  30. Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5α-reductase-2 deficiency. Mol Cell Endocrinol. 2002;198:51–59
  31. Andersson S, Berman DM, Jenkins EP, et al. Deletion of steroid 5 α-reductase 2 gene in male pseudohermaphroditism. Nature. 1991;354:159–161
  32. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA. 1990;87:3640–3644
  33. Jenkins EP, Andersson S, Imperato-McGinley J, et al. Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest. 1992;89:293–300
  34. Uemura M, Tamura K, Chung S, et al. Novel 5α-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci. 2008;99:81–86
  35. Bonkhoff H, Stein U, Aumuller G, et al. Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate. 1996;29:261–267
  36. Iehle C, Radvanyi F, Diezde G, et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol. 1999;68:189–195
  37. Pelletier G, Luu-The V, Huang XF, et al. Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin. J Urol. 1998;160:577–582
  38. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5α-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol. 2008;179:1235–1242
  39. Ross RK, Bernstein L, Lobo RA, et al. 5-Alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339:887–889
  40. Lookingbill DP, Demers LM, Wang C, et al. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab. 1991;72:1242–1248
  41. Wu AH, Whittemore AS, Kolonel LN, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995;4:735–741
  42. Litman HJ, Bhasin S, Link CL, et al. Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab. 2006;91:4326–4334
  43. Singh RP, Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer. 2006;13:751–778
  44. Hoedemaeker RF, van der Kwast TH, Boer R, et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst. 2001;93:1153–1158
  45. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308
  46. Thomas LN, Douglas RC, Vessey JP, et al. 5α-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol. 2003;170:2019–2025
  47. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5α-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate. 2005;63:231–239
  48. Thomas LN, Douglas RC, Lazier CB, et al. Levels of 5α-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol. 2008;179:147–151
  49. Andriole G, Bostwick D, Civantos F, et al. The effects of 5α-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol. 2005;174:2098–2104
  50. Rittmaster RS. 5α-Reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab. 2008;22:389–402
  51. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001
  52. Hsieh AC, Ryan CJ. Novel concepts in androgen receptor blockade. Cancer J. 2008;14:11–14
  53. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  54. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521–1517
  55. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol. 2004;172(4 Pt. 1):1314–1317

 E. D. Crawford serves as a consultant and speaker for GlaxoSmithKline, Sanofi-Aventis, and AstraZeneca and receives grant support from the National Institutes of Health and Endocare.

PII: S0090-4295(09)00284-2

doi: 10.1016/j.urology.2009.03.001

Urology
Volume 73, Issue 5, Supplement , Pages S4-S10 , May 2009

Article Tools

* Image Usage & Resolution